Jubilant Pharmova Ltd

Jubilant Pharmova Ltd is rated Sell by MarketsMOJO, with this rating last updated on 10 April 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 24 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Jubilant Pharmova Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 10 April 2026, reflecting nuanced shifts across technical indicators and valuation metrics despite ongoing financial challenges. This recalibration follows a detailed analysis of the company’s quality, valuation, financial trends, and technical outlook, providing investors with a clearer perspective on its current market positioning within the Pharmaceuticals & Biotechnology sector.

Jubilant Pharmova Ltd has exhibited a nuanced shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook, reflecting a complex interplay of technical indicators. Despite a modest day gain of 1.26%, the stock’s broader trend signals caution amid mixed signals from MACD, RSI, and moving averages, underscoring the challenges facing this small-cap pharmaceutical player in a volatile market environment.

Jubilant Pharmova Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 06 February 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 08 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Jubilant Pharmova Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 06 February 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 28 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and overall outlook.

The Sensex gained 2.05% on 24 Mar 2026, yet Jubilant Pharmova Ltd outpaced the broader market with a 7.07% surge, reaching an intraday high of Rs 874.55. This 6.15 percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers signals a distinctly stock-specific rally rather than a mere market lift.

Jubilant Pharmova Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 06 February 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 17 March 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook.

Jubilant Pharmova Ltd’s stock declined sharply to a fresh 52-week low of Rs.783.75 on 10 Mar 2026, marking a significant downturn amid broader market volatility and company-specific headwinds. The stock underperformed its sector and broader indices, reflecting ongoing concerns about its financial performance and valuation metrics.

Jubilant Pharmova Ltd’s stock declined to a fresh 52-week low of Rs.786.55 on 9 Mar 2026, marking a significant drop amid broader market weakness and company-specific performance concerns. The stock has been under pressure for the past two sessions, reflecting a cumulative fall of 3.31% during this period.

Jubilant Pharmova Ltd’s shares declined to a fresh 52-week low of Rs.819 today, marking a significant downturn amid broader market weakness and company-specific performance concerns. The stock underperformed its sector and key benchmarks, reflecting ongoing pressures on its financial metrics and valuation.

Jubilant Pharmova Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 06 February 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 06 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Jubilant Pharmova Ltd’s stock price declined sharply to a new 52-week low of Rs.820.05 on 2 March 2026, marking a significant milestone in its recent downward trajectory. The stock has underperformed its sector and broader market indices, reflecting ongoing pressures on its financial performance and valuation metrics.

Jubilant Pharmova Ltd commenced trading today with a pronounced gap down, opening at a price 5.34% lower than its previous close, reflecting heightened market apprehension. The stock hit a fresh 52-week low of Rs. 820.05 amid continued downward momentum, underperforming its sector and broader indices.

Jubilant Pharmova Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 06 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Jubilant Pharmova Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 06 February 2026. However, all fundamentals, returns, and financial metrics discussed here reflect the stock's current position as of 23 February 2026, providing investors with an up-to-date analysis of the company’s standing.

Jubilant Pharmova Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 06 February 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 11 February 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Jubilant Pharmova Ltd has reported a marked deterioration in its financial performance for the quarter ended December 2025, with key metrics signalling a shift from prior stability to negative trends. Despite achieving record net sales, the company’s profitability and margin indicators have contracted sharply, prompting a downgrade in its Mojo Grade to Strong Sell.